Risk factors and outcome of bacterial infections in cirrhosis

World Journal of Gastroenterology

Volumn 20, Issue 10, 2014, Pages 2542-2554

  Bruns, Tony ^a   Zimmermann, Henning W ^b   Stallmach, Andreas ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Bacterial translocation; Chronic liver disease; Cirrhosis; Immunity; Infection; Mortality; Risk factors

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL DNA; C REACTIVE PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MURAMYL DIPEPTIDE; PROTON PUMP INHIBITOR; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; ANTIINFECTIVE AGENT; AUTACOID;

ACUTE KIDNEY FAILURE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; CAID SYNDROME; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; GASTROINTESTINAL HEMORRHAGE; GENETIC ASSOCIATION; HEPATORENAL SYNDROME; HUMAN; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LIVER FAILURE; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PORTAL HYPERTENSION; RISK FACTOR; SCORING SYSTEM; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; SYNDROME; URINARY TRACT INFECTION; ANIMAL; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; COMPLICATION; DISEASE COURSE; HEMODYNAMICS; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; BACTERIAL TRANSLOCATION; DISEASE PROGRESSION; HEMODYNAMICS; HUMANS; INFLAMMATION MEDIATORS; LIVER CIRRHOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896886697     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i10.2542     Document Type: Article

References (155)

1. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 353-358 [PMID: 8228129]
2. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S, Colloredo-Mels G, Corigliano P, Fornaciari G, Marenco G, Pistarà R, Salvagnini M, Sangiovanni A. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41-48 [PMID: 11303974]
3. Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-148 [PMID: 11786970]
4. Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Ginès P, Arroyo V. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-1561 [PMID: 22183941 DOI: 10.1002/hep.25532]
5. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-137, 1426-137, [PMID: 23474284 DOI: 10.1053/ j.gastro.2013.02.042]
6. Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Burroughs AK. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-156, 1246-156, [PMID: 20558165 DOI: 10.1053/ j.gastro.2010.06.019]
7. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012; 61: 297-310 [PMID: 22147550 DOI: 10.1136/gutjnl-2011-300779]
8. Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9: 727-738 [PMID: 21397731 DOI: 10.1016/j.cgh.2011.02.031]
9. Bruns T, Stallmach A. [Spontaneous and Secondary Bacterial Peritonitis in Cirrhotic Patients with Ascites.] Zentralbl Chir 2011; Epub ahead of print [PMID: 22144140 DOI: 10.1055/ s-0031-1283815]
10. Arabi YM, Dara SI, Memish Z, Al Abdulkareem A, Tamim HM, Al-Shirawi N, Parrillo JE, Dodek P, Lapinsky S, Feinstein D, Wood G, Dial S, Zanotti S, Kumar A. Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis. Hepatology 2012; 56: 2305-2315 [PMID: 22753144 DOI: 10.1002/hep.25931]
11. Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritoni-tis. J Hepatol 1994; 21: 792-796 [PMID: 7890896]
12. Scarpellini E, Valenza V, Gabrielli M, Lauritano EC, Perotti G, Merra G, Dal Lago A, Ojetti V, Ainora ME, Santoro M, Ghirlanda G, Gasbarrini A. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol 2010; 105: 323-327 [PMID: 19844200 DOI: 10.1038/ajg.2009.558]
13. Teltschik Z, Wiest R, Beisner J, Nuding S, Hofmann C, Schoelmerich J, Bevins CL, Stange EF, Wehkamp J. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology 2012; 55: 1154-1163 [PMID: 22095436 DOI: 10.1002/ hep.24789]
14. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-433 [PMID: 15723320 DOI: 10.1002/hep.20632]
15. Steffen EK, Berg RD, Deitch EA. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis 1988; 157: 1032-1038 [PMID: 3283254 DOI: 10.1093/ infdis/157.5.1032]
16. Bert F, Johnson JR, Ouattara B, Leflon-Guibout V, Johnston B, Marcon E, Valla D, Moreau R, Nicolas-Chanoine MH. Genetic diversity and virulence profiles of Escherichia coli isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. J Clin Microbiol 2010; 48: 2709-2714 [PMID: 20519468 DOI: 10.1128/JCM.00516-10]
17. Katouli M, Nettebladt CG, Muratov V, Ljungqvist O, Bark T, Svenberg T, Möllby R. Selective translocation of coliform bacteria adhering to caecal epithelium of rats during catabolic stress. J Med Microbiol 1997; 46: 571-578 [PMID: 9236741]
18. Macutkiewicz C, Carlson G, Clark E, Dobrindt U, Roberts I, Warhurst G. Characterisation of Escherichia coli strains involved in transcytosis across gut epithelial cells exposed to metabolic and inflammatory stress. Microbes Infect 2008; 10: 424-431 [PMID: 18403240 DOI: 10.1016/j.micinf.2008.01.001]
19. Clark E, Hoare C, Tanianis-Hughes J, Carlson GL, Warhurst G. Interferon gamma induces translocation of commensal Escherichia coli across gut epithelial cells via a lipid raft-mediated process. Gastroenterology 2005; 128: 1258-1267 [PMID: 15887109 DOI: 10.1053/j.gastro.2005.01.046]
20. Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, Fuster J, García-Valdecasas JC, Lacy A, Suárez MJ, Rimola A, Rodés J. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32-37 [PMID: 11211904 DOI: 10.1016/S0168-8278(00)00013-1]
21. O'Boyle CJ, MacFie J, Mitchell CJ, Johnstone D, Sagar PM, Sedman PC. Microbiology of bacterial translocation in humans. Gut 1998; 42: 29-35 [PMID: 9505882 DOI: 10.1136/ gut.42.1.29]
22. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995; 108: 1835-1841 [PMID: 7768390]
23. Pérez-Paramo M, Muñoz J, Albillos A, Freile I, Portero F, Santos M, Ortiz-Berrocal J. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000; 31: 43-48 [PMID: 10613726 DOI: 10.1002/hep.510310109]
24. Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, Burroughs AK. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29: 1189-1193 [PMID: 19508620 DOI: 10.1111/j.1478-3231.2009.02038.x]
25. Úbeda M, Muñoz L, Borrero MJ, Díaz D, Francés R, Monserrat J, Lario M, Lledó L, Such J, Álvarez-Mon M, Albillos A. Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. Hepatology 2010; 52: 2086-2095 [PMID: 21105108 DOI: 10.1002/hep.23961]
26. Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 2013; 58: 911-921 [PMID: 23262249 DOI: 10.1016/j.jhep.2012.12.011]
27. Kasravi FB, Wang L, Wang XD, Molin G, Bengmark S, Jeppsson B. Bacterial translocation in acute liver injury induced by D-galactosamine. Hepatology 1996; 23: 97-103 [PMID: 8550055 DOI: 10.1002/hep.510230114]
28. Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology 1993; 17: 1081-1085 [PMID: 8514258]
29. Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 2002; 97: 2364-2370 [PMID: 12358257 DOI: 10.1111/ j.1572-0241.2002.05791.x]
30. Jun DW, Kim KT, Lee OY, Chae JD, Son BK, Kim SH, Jo YJ, Park YS. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci 2010; 55: 1465-1471 [PMID: 19517230 DOI: 10.1007/s10620-009-0870-9]
31. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998; 28: 1187-1190 [PMID: 9794900 DOI: 10.1002/hep.510280504]
32. Lorenzo-Zúñiga V, Bartolí R, Planas R, Hofmann AF, Viñado B, Hagey LR, Hernández JM, Mañé J, Alvarez MA, Ausina V, Gassull MA. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003; 37: 551-557 [PMID: 12601352 DOI: 10.1053/jhep.2003.50116]
33. Van Bossuyt H, Desmaretz C, Gaeta GB, Wisse E. The role of bile acids in the development of endotoxemia during obstructive jaundice in the rat. J Hepatol 1990; 10: 274-279 [PMID: 2365979]
34. Suzuki T, Yoshinaga N, Tanabe S. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J Biol Chem 2011; 286: 31263-31271 [PMID: 21771795 DOI: 10.1074/jbc.M111.238147]
35. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003; 171: 6164-6172 [PMID: 14634132]
36. Campillo B, Pernet P, Bories PN, Richardet JP, Devanlay M, Aussel C. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol 1999; 11: 755-759 [PMID: 10445796]
37. Campillo B, Richardet JP, Kheo T, Dupeyron C. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis 2002; 35: 1-10 [PMID: 12060868 DOI: 10.1086/340617]
38. Benjamin J, Singla V, Arora I, Sood S, Joshi YK. Intestinal permeability and complications in liver cirrhosis: A prospective cohort study. Hepatol Res 2013; 43: 200-207 [PMID: 22726344 DOI: 10.1111/j.1872-034X.2012.01054.x]
39. Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011; 54: 562-572 [PMID: 21574172 DOI: 10.1002/hep.24423]
40. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol 2011; 61: 693-703 [PMID: 21286703 DOI: 10.1007/ s00248-010-9801-8]
41. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-1449 [PMID: 15122774 DOI: 10.1002/ hep.20194]
42. Kuo CH, Changchien CS, Yang CY, Sheen IS, Liaw YF. Bacteremia in patients with cirrhosis of the liver. Liver 1991; 11: 334-339 [PMID: 1779712]
43. Reuken PA, Pletz MW, Baier M, Pfister W, Stallmach A, Bruns T. Emergence of spontaneous bacterial peritonitis due to enterococci-risk factors and outcome in a 12-year retrospective study. Aliment Pharmacol Ther 2012; 35: 1199-1208 [PMID: 22449290 DOI: 10.1111/j.1365-2036.2012.05076.x]
44. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303: G675-G685 [PMID: 22821944 DOI: 10.1152/ ajpgi.00152.2012]
45. Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Sikaroodi M, Gillevet PM. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302: G168-G175 [PMID: 21940902 DOI: 10.1152/ajpgi.00190.2011]
46. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, Peaper DR, Bertin J, Eisenbarth SC, Gordon JI, Flavell RA. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145: 745-757 [PMID: 21565393 DOI: 10.1016/j.cell.2011.04.022]
47. Sun Y, Zhang M, Chen CC, Gillilland M, Sun X, El-Zaatari M, Huffnagle GB, Young VB, Zhang J, Hong SC, Chang YM, Gumucio DL, Owyang C, Kao JY. Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 2013; 144: 1478-187, 1478-187, [PMID: 23470617 DOI: 10.1053/j.gastro.2013.02.038]
48. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185 [PMID: 22297845 DOI: 10.1038/nature10809]
49. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014; 60: 197-209 [PMID: 23993913 DOI: 10.1016/j.jhep.2013.07.044]
50. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723-737 [PMID: 21997792 DOI: 10.1038/nri3073]
51. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-483 [PMID: 19105661 DOI: 10.1146/annurev.immunol.021908.132532]
52. Zimmermann HW, Reuken PA, Koch A, Bartneck M, Adams DH, Trautwein C, Stallmach A, Tacke F, Bruns T. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. J Intern Med 2013; 274: 86-100 [PMID: 23432143 DOI: 10.1111/joim.12054]
53. Saba TM. Physiology and physiopathology of the reticuloendothelial system. Arch Intern Med 1970; 126: 1031-1052 [PMID: 4921754]
54. Zimmermann HW, Trautwein C, Tacke F. Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol 2012; 3: 56 [PMID: 23091461 DOI: 10.3389/fphys.2012.00056]
55. Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984; 4: 53-58 [PMID: 6693068]
56. Bolognesi M, Merkel C, Bianco S, Angeli P, Sacerdoti D, Amodio P, Gatta A. Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Hepatology 1994; 19: 628-634 [PMID: 8119687]
57. Petermann H, Heymann S, Vogl S, Dargel R. Phagocytic function and metabolite production in thioacetamide-induced liver cirrhosis: a comparative study in perfused livers and cultured Kupffer cells. J Hepatol 1996; 24: 468-477 [PMID: 8738734]
58. Homann C, Garred P, Hasselqvist P, Graudal N, Thiel S, Thomsen AC. Mannan-binding protein and complement dependent opsonization in alcoholic cirrhosis. Liver 1995; 15: 39-44 [PMID: 7776856]
59. Albillos A, Hera Ad Ade L, Reyes E, Monserrat J, Muñoz L, Nieto M, Prieto A, Sanz E, Alvarez-Mon M. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J Hepatol 2004; 40: 624-631 [PMID: 15030978 DOI: 10.1016/j.jhep.2003.12.010]
60. Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, Tischendorf JJ, Luedde T, Weiskirchen R, Trautwein C, Tacke F. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 2010; 5: e11049 [PMID: 20548789 DOI: 10.1371/journal.pone.0011049]
61. Holland-Fischer P, Grønbæk H, Sandahl TD, Moestrup SK, Riggio O, Ridola L, Aagaard NK, Møller HJ, Vilstrup H. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut 2011; 60: 1389-1393 [PMID: 21572121 DOI: 10.1136/gut.2010.234542]
62. Fiuza C, Salcedo M, Clemente G, Tellado JM. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis 2000; 182: 526-533 [PMID: 10915084 DOI: 10.1086/315742]
63. Ono Y, Watanabe T, Matsumoto K, Ito T, Kunii O, Goldstein E. Opsonophagocytic dysfunction in patients with liver cirrhosis and low responses to tumor necrosis factoralpha and lipopolysaccharide in patients' blood. J Infect Chemother 2004; 10: 200-207 [PMID: 15365859 DOI: 10.1007/ s10156-004-0321-7]
64. Shawcross DL, Wright GA, Stadlbauer V, Hodges SJ, Davies NA, Wheeler-Jones C, Pitsillides AA, Jalan R. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 2008; 48: 1202-1212 [PMID: 18697192 DOI: 10.1002/ hep.22474]
65. Bruns T, Peter J, Hagel S, Herrmann A, Stallmach A. The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection. Clin Exp Immunol 2011; 164: 346-356 [PMID: 21413941 DOI: 10.1111/j.1365-2249.2011.04373.x]
66. Tritto G, Bechlis Z, Stadlbauer V, Davies N, Francés R, Shah N, Mookerjee RP, Such J, Jalan R. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol 2011; 55: 574-581 [PMID: 21236309 DOI: 10.1016/ j.jhep.2010.11.034]
67. Mookerjee RP, Stadlbauer V, Lidder S, Wright GA, Hodges SJ, Davies NA, Jalan R. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007; 46: 831-840 [PMID: 17680644 DOI: 10.1002/hep.21737]
68. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986; 6: 252-262 [PMID: 3007318]
69. Márquez M, Fernández-Gutiérrez C, Montes-de-Oca M, Blanco MJ, Brun F, Rodríguez-Ramos C, Girón-González JA. Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis. Clin Exp Immunol 2009; 158: 219-229 [PMID: 19737142 DOI: 10.1111/ j.1365-2249.2009.04005.x]
70. Lario M, Muñoz L, Ubeda M, Borrero MJ, Martínez J, Monserrat J, Díaz D, Alvarez-Mon M, Albillos A. Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis. J Hepatol 2013; 59: 723-730 [PMID: 23742913 DOI: 10.1016/ j.jhep.2013.05.042]
71. Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, Baumgarten R, Wiese M, Fourneau M, Safary A, Clemens R, Krause DS. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27: 881-886 [PMID: 9500723 DOI: 10.1002/ hep.510270336]
72. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000; 14 Suppl B: 59B-62B [PMID: 10938507]
73. Cheong HJ, Song JY, Park JW, Yeon JE, Byun KS, Lee CH, Cho HI, Kim TG, Kim WJ. Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis. Vaccine 2006; 24: 2417-2422 [PMID: 16406176 DOI: 10.1016/j.vaccine.2005.11.064]
74. Schirren CA, Jung MC, Zachoval R, Diepolder H, Hoffmann R, Riethmüller G, Pape GR. Analysis of T cell activation pathways in patients with liver cirrhosis, impaired delayed hypersensitivity and other T cell-dependent functions. Clin Exp Immunol 1997; 108: 144-150 [PMID: 9097923 DOI: 10.1046/j.1365-2249.1997.d01-985.x]
75. Peter J, Frey O, Stallmach A, Bruns T. Attenuated antigenspecific T cell responses in cirrhosis are accompanied by elevated serum interleukin-10 levels and down-regulation of HLA-DR on monocytes. BMC Gastroenterol 2013; 13: 37 [PMID: 23446058 DOI: 10.1186/1471-230X-13-37]
76. Hsu CC, Leevy CM. Inhibition of PHA-stimulated lymphocyte transformation by plasma from patients with advanced alcoholic cirrhosis. Clin Exp Immunol 1971; 8: 749-760 [PMID: 5581064]
77. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993; 81: 2964-2971 [PMID: 8499633]
78. Chuang WL, Liu HW, Chang WY, Chen SC, Hsieh MY, Wang LY. Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage. Dig Dis Sci 1991; 36: 299-302 [PMID: 1995265]
79. Zimmermann HW, Mueller JR, Seidler S, Luedde T, Trautwein C, Tacke F. Frequency and phenotype of human circulating and intrahepatic natural killer cell subsets is differentially regulated according to stage of chronic liver disease. Digestion 2013; 88: 1-16 [PMID: 23774822 DOI: 10.1159/000350821]
80. Doi H, Iyer TK, Carpenter E, Li H, Chang KM, Vonderheide RH, Kaplan DE. Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population. Hepatology 2012; 55: 709-719 [PMID: 21932384 DOI: 10.1002/hep.24689]
81. Byl B, Roucloux I, Crusiaux A, Dupont E, Devière J. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology 1993; 104: 1492-1497 [PMID: 8482461]
82. Abdel-Khalek EE, El-Fakhry A, Helaly M, Hamed M, Elbaz O. Systemic inflammatory response syndrome in patients with liver cirrhosis. Arab J Gastroenterol 2011; 12: 173-177 [PMID: 22305496 DOI: 10.1016/j.ajg.2011.11.006]
83. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009; 51: 475-482 [PMID: 19560225 DOI: 10.1016/j.jhep.2009.04.017]
84. Reuken PA, Stallmach A, Bruns T. Mortality after urinary tract infections in patients with advanced cirrhosis-Relevance of acute kidney injury and comorbidities. Liver Int 2013; 33: 220-230 [PMID: 23295053 DOI: 10.1111/liv.12029]
85. Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, Duhamel C, Lebrec D, Poynard T, Moreau R. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007; 46: 1872-1882 [PMID: 17972337 DOI: 10.1002/ hep.21920]
86. Rosenbloom AJ, Pinsky MR, Bryant JL, Shin A, Tran T, Whiteside T. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction. JAMA 1995; 274: 58-65 [PMID: 7540697]
87. Lee FY, Lu RH, Tsai YT, Lin HC, Hou MC, Li CP, Liao TM, Lin LF, Wang SS, Lee SD. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. Scand J Gastroenterol 1996; 31: 500-505 [PMID: 8734349]
88. Cervoni JP, Thévenot T, Weil D, Muel E, Barbot O, Sheppard F, Monnet E, Di Martino V. C-reactive protein predicts shortterm mortality in patients with cirrhosis. J Hepatol 2012; 56: 1299-1304 [PMID: 22314431 DOI: 10.1016/j.jhep.2011.12.030]
89. Tsiakalos A, Karatzaferis A, Ziakas P, Hatzis G. Acutephase proteins as indicators of bacterial infection in patients with cirrhosis. Liver Int 2009; 29: 1538-1542 [PMID: 19659507 DOI: 10.1111/j.1478-3231.2009.02088.x]
90. Reuken PA, Kiehntopf M, Stallmach A, Bruns T. Midregional pro-adrenomedullin (MR-proADM): an even better prognostic biomarker than C-reactive protein to predict short-term survival in patients with decompensated cirrhosis at risk of infection? J Hepatol 2012; 57: 1156-118; author reply 1156-118; [PMID: 22892248 DOI: 10.1016/j.jhep.2012.06.036]
91. Lazzarotto C, Ronsoni MF, Fayad L, Nogueira CL, Bazzo ML, Narciso-Schiavon JL, de Lucca Schiavon L, Dantas-Corrêa EB. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol 2013; 12: 599-607 [PMID: 23813138]
92. Bruns T, Sachse S, Straube E, Assefa S, Herrmann A, Hagel S, Lehmann M, Stallmach A. Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver Int 2009; 29: 1206-1214 [PMID: 19602138 DOI: 10.1111/ j.1478-3231.2009.02073.x]
93. Guggenbichler JP, Allerberger FJ, Dierich M. Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy. Padiatr Padol 1986; 21: 335-342 [PMID: 3562044]
94. Gerbes AL, Gülberg V, Sauerbruch T, Wiest R, Appenrodt B, Bahr MJ, Dollinger MM, Rössle M, Schepke M. [German S 3-guideline "ascites, spontaneous bacterial peritonitis, hepatorenal syndrome"]. Z Gastroenterol 2011; 49: 749-779 [PMID: 21638242 DOI: 10.1055/s-0031-1273405]
95. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417 [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004]
96. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010; (9): CD002907 [PMID: 20824832 DOI: 10.1002/14651858.CD002907.pub2]
97. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, Uribe M. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding-an updated Cochrane review. Aliment Pharmacol Ther 2011; 34: 509-518 [PMID: 21707680 DOI: 10.1111/j.1365-2036.2011.04746.x]
98. Banerjee S, Shen B, Baron TH, Nelson DB, Anderson MA, Cash BD, Dominitz JA, Gan SI, Harrison ME, Ikenberry SO, Jagannath SB, Lichtenstein D, Fanelli RD, Lee K, van Guilder T, Stewart LE. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc 2008; 67: 791-798 [PMID: 18374919 DOI: 10.1016/j.gie.2008.02.068]
99. Llach J, Elizalde JI, Bordas JM, Gines A, Almela M, Sans M, Mondelo F, Pique JM. Prospective assessment of the risk of bacteremia in cirrhotic patients undergoing lower intestinal endoscopy. Gastrointest Endosc 1999; 49: 214-217 [PMID: 9925701]
100. Hirota WK, Petersen K, Baron TH, Goldstein JL, Jacobson BC, Leighton JA, Mallery JS, Waring JP, Fanelli RD, Wheeler-Harbough J, Faigel DO. Guidelines for antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc 2003; 58: 475-482 [PMID: 14520276]
101. Baron TH. Antibiotic prophylaxis for colonoscopy in cirrhotics. Liver Transpl 2006; 12: 493-493[DOI: 10.1002/lt.20646]
102. Guarner C, Solà R, Soriano G, Andreu M, Novella MT, Vila MC, Sàbat M, Coll S, Ortiz J, Gómez C, Balanzó J. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999; 117: 414-419 [PMID: 10419924]
103. Titó L, Rimola A, Ginès P, Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27-31 [PMID: 3257456]
104. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107 [PMID: 19475696 DOI: 10.1002/hep.22853]
105. Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824 [PMID: 17854593 DOI: 10.1053/j.gastro.2007.06.065]
106. Saab S, Hernandez JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a metaanalysis. Am J Gastroenterol 2009; 104: 993-1001; quiz 1002 [PMID: 19277033 DOI: 10.1038/ajg.2009.3]
107. Thevenot T, Degand T, Grelat N, Elkrief L, Christol C, Moreau R, Henrion J, Cadranel JF, Sheppard F, Bureau C, di Martino V, Pauwels A. A French national survey on the use of antibiotic prophylaxis in cirrhotic patients. Liver Int 2013; 33: 389-397 [PMID: 23302021 DOI: 10.1111/liv.12093]
108. Ngamruengphong S, Nugent K, Rakvit A, Parupudi S. Potential preventability of spontaneous bacterial peritonitis. Dig Dis Sci 2011; 56: 2728-2734 [PMID: 21394460 DOI: 10.1007/s10620-011-1647-5]
109. Gäbele E, Mühlbauer M, Paulo H, Johann M, Meltzer C, Leidl F, Wodarz N, Wiest R, Schölmerich J, Hellerbrand C. Analysis of monocyte chemotactic protein-1 gene polymorphism in patients with spontaneous bacterial peritonitis. World J Gastroenterol 2009; 15: 5558-5562 [PMID: 19938194 DOI: 10.3748/wjg.15.5558]
110. Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010; 51: 1327-1333 [PMID: 20087966 DOI: 10.1002/hep.23440]
111. Bruns T, Peter J, Reuken PA, Grabe DH, Schuldes SR, Brenmoehl J, Schölmerich J, Wiest R, Stallmach A. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int 2012; 32: 223-230 [PMID: 21745302 DOI: 10.1111/j.1478-3231.2011.02561.x]
112. Nischalke HD, Berger C, Aldenhoff K, Thyssen L, Gentemann M, Grünhage F, Lammert F, Nattermann J, Sauerbruch T, Spengler U, Appenrodt B. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol 2011; 55: 1010-1016 [PMID: 21356257 DOI: 10.1016/j.jhep.2011.02.022]
113. Bruns T, Reuken PA, Fischer J, Berg T, Stallmach A. Further evidence for the relevance of TLR2 gene variants in spontaneous bacterial peritonitis. J Hepatol 2012; 56: 1207-128; author reply 1207-128; [PMID: 22019578 DOI: 10.1016/ j.jhep.2011.09.010]
114. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell RA. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-734 [PMID: 15692051 DOI: 10.1126/science. 1104911]
115. Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhães JG, Yuan L, Soares F, Chea E, Le Bourhis L, Boneca IG, Allaoui A, Jones NL, Nuñez G, Girardin SE, Philpott DJ. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11: 55-62 [PMID: 19898471 DOI: 10.1038/ni.1823]
116. Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, Ogunbiyi O, Nuñez G, Keshav S. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003; 125: 47-57 [PMID: 12851870 DOI: 10.1016/S0016-5085(03)00661-9]
117. Obstein KL, Campbell MS, Reddy KR, Yang YX. Association between model for end-stage liver disease and spontaneous bacterial peritonitis. Am J Gastroenterol 2007; 102: 2732-2736 [PMID: 17714556 DOI: 10.1111/j.1572-0241.2007.01485.x]
118. Rosa H, Silvério AO, Perini RF, Arruda CB. Bacterial infection in cirrhotic patients and its relationship with alcohol. Am J Gastroenterol 2000; 95: 1290-1293 [PMID: 10811341 DOI: 10.1111/j.1572-0241.2000.02026.x]
119. Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, Rolston DD, Sferra TJ, Hernandez AV. Acidsuppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol 2013; 28: 235-242 [PMID: 23190338 DOI: 10.1111/ jgh.12065]
120. de Vos M, De Vroey B, Garcia BG, Roy C, Kidd F, Henrion J, Deltenre P. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver Int 2013; 33: 1316-1323 [PMID: 23730823 DOI: 10.1111/liv.12210]
121. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, Salinas F, Donà S, Fagiuoli S, Sticca A, Zanus G, Cillo U, Frasson I, Destro C, Gatta A. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45: 223-229 [PMID: 17187409 DOI: 10.1002/hep.21443]
122. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, Noble NA, Thacker LR, Kamath PS. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 2012; 56: 2328-2335 [PMID: 22806618 DOI: 10.1002/hep.25947]
123. Hung TH, Tseng CW, Hsieh YH, Tseng KC, Tsai CC, Tsai CC. High mortality of pneumonia in cirrhotic patients with ascites. BMC Gastroenterol 2013; 13: 25 [PMID: 23390924 DOI: 10.1186/1471-230X-13-25]
124. Mellencamp MA, Preheim LC. Pneumococcal pneumonia in a rat model of cirrhosis: effects of cirrhosis on pulmonary defense mechanisms against Streptococcus pneumoniae. J Infect Dis 1991; 163: 102-108 [PMID: 1984456]
125. Falguera M, Trujillano J, Caro S, Menéndez R, Carratalà J, Ruiz-González A, Vilà M, García M, Porcel JM, Torres A. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis 2009; 49: 409-416 [PMID: 19555286 DOI: 10.1086/600291]
126. Di Pasquale M, Esperatti M, Crisafulli E, Ferrer M, Bassi GL, Rinaudo M, Escorsell A, Fernandez J, Mas A, Blasi F, Torres A. Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study. Intensive Care Med 2013; 39: 1776-1784 [PMID: 23907496 DOI: 10.1007/ s00134-013-3025-6]
127. Leise MD, Talwalkar JA. Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep 2013; 15: 300 [PMID: 23250700 DOI: 10.1007/s11894-012-0300-6]
128. McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000; 181: 757-760 [PMID: 10669371 DOI: 10.1086/315245]
129. Pereira G, Guevara M, Fagundes C, Solá E, Rodríguez E, Fernández J, Pavesi M, Arroyo V, Ginès P. Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol 2012; 56: 1040-1046 [PMID: 22245902 DOI: 10.1016/j.jhep.2011.11.023]
130. Mohan P, Ramu B, Bhaskar E, Venkataraman J. Prevalence and risk factors for bacterial skin infection and mortality in cirrhosis. Ann Hepatol 2011; 10: 15-20 [PMID: 21301004]
131. Hung TH, Hsieh YH, Tseng KC, Tsai CC, Tsai CC. The risk for bacterial endocarditis in cirrhotic patients: a populationbased 3-year follow-up study. Int J Infect Dis 2013; 17: e391-e393 [PMID: 23352807 DOI: 10.1016/j.ijid.2012.12.009]
132. Fernández Guerrero ML, González López J, Górgolas M. Infectious endocarditis in patients with cirrhosis of the liver: a model of infection in the frail patient. Eur J Clin Microbiol Infect Dis 2010; 29: 1271-1275 [PMID: 20549527 DOI: 10.1007/ s10096-010-0998-8]
133. Barahona-Garrido J, Hernández-Calleros J, Téllez-Avila FI, Chávez-Tapia NC, Remes-Troche JM, Torre A. Bacterial meningitis in cirrhotic patients: case series and description of the prognostic role of acute renal failure. J Clin Gastroenterol 2010; 44: e218-e223 [PMID: 20453662 DOI: 10.1097/ MCG.0b013e3181d88d53]
134. Pauwels A, Pinès E, Abboura M, Chiche I, Lévy VG. Bacterial meningitis in cirrhosis: review of 16 cases. J Hepatol 1997; 27: 830-834 [PMID: 9382970]
135. Tandon P, Kumar D, Seo YS, Chang HJ, Chaulk J, Carbonneau M, Qamar H, Keough A, Mansoor N, Ma M. The 22/11 risk prediction model: a validated model for predicting 30-day mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Am J Gastroenterol 2013; 108: 1473-1479 [PMID: 23877350 DOI: 10.1038/ajg.2013.204]
136. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290 [PMID: 19776409 DOI: 10.1056/NEJMra0809139]
137. Newby DE, Hayes PC. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but 'splanchnic steal'. QJM 2002; 95: 827-830 [PMID: 12454326 DOI: 10.1093/ qjmed/95.12.827]
138. Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest 1967; 46: 1894-1906 [PMID: 6073996 DOI: 10.1172/ JCI105679]
139. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 1819-1827 [PMID: 14654322 DOI: 10.1016/S0140-6736(03)14903-3]
140. Terra C, Guevara M, Torre A, Gilabert R, Fernández J, Martín-Llahí M, Baccaro ME, Navasa M, Bru C, Arroyo V, Rodés J, Ginès P. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129: 1944-1953 [PMID: 16344063 DOI: 10.1053/j.gastro.2005.09.024]
141. Barreto R, Fagundes C, Guevara M, Solà E, Pereira G, Rodríguez E, Graupera I, Martín-Llahí M, Ariza X, Cárdenas A, Fernández J, Rodés J, Arroyo V, Ginès P. Type-1 hepatorenal syndrome associated with infections in cirrhosis. Natural history, outcome of kidney function and survival. Hepatology 2013; Epub ahead of print [PMID: 24037970 DOI: 10.1002/ hep.26687]
142. Wong F, O'Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, Garcia-Tsao G, Subramanian RM, Malik R, Maliakkal B, Thacker LR, Bajaj JS. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 2013; 145: 1280-8. e1 [PMID: 23999172 DOI: 10.1053/ j.gastro.2013.08.051]
143. Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, Solá E, Pereira G, Marinelli M, Pavesi M, Fernández J, Rodés J, Arroyo V, Ginès P. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 488-496. e4 [PMID: 20682324 DOI: 10.1053/j.gastro.2010.07.043]
144. Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, Parikh CR. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013; 57: 753-762 [PMID: 22454364 DOI: 10.1002/hep.25735]
145. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409 [PMID: 10432325 DOI: 10.1056/NEJM199908053410603]
146. Guevara M, Terra C, Nazar A, Solà E, Fernández J, Pavesi M, Arroyo V, Ginès P. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol 2012; 57: 759-765 [PMID: 22732511 DOI: 10.1016/j.jhep.2012.06.013]
147. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648 [PMID: 11113085]
148. Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, Saliba F, Carbonell N, Renard P, Ramond MJ, Moreau R, Poynard T. Pentoxifylline does not decrease shortterm mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 1755-1762 [PMID: 20102716 DOI: 10.1053/j.gastro.2010.01.040]
149. Tyagi P, Sharma P, Sharma BC, Puri AS, Kumar A, Sarin SK. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. Eur J Gastroenterol Hepatol 2011; 23: 210-217 [PMID: 21285885 DOI: 10.1097/ MEG.0b013e3283435d76]
150. Cheong HS, Kang CI, Lee JA, Moon SY, Joung MK, Chung DR, Koh KC, Lee NY, Song JH, Peck KR. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009; 48: 1230-1236 [PMID: 19302016 DOI: 10.1086/597585]
151. Umgelter A, Reindl W, Miedaner M, Schmid RM, Huber W. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 2009; 37: 2-8 [PMID: 19169633 DOI: 10.1007/ s15010-008-8060-9]
152. Song KH, Jeon JH, Park WB, Park SW, Kim HB, Oh MD, Lee HS, Kim NJ, Choe KW. Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum betalactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study. BMC Infect Dis 2009; 9: 41 [PMID: 19361340 DOI: 10.1186/1471-2334-9-41]
153. Sandiumenge A, Diaz E, Bodí M, Rello J. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 2003; 29: 876-883 [PMID: 12677369 DOI: 10.1007/ s00134-003-1715-1]
154. Ariza X, Castellote J, Lora-Tamayo J, Girbau A, Salord S, Rota R, Ariza J, Xiol X. Risk factors for resistance to ceftri-axone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012; 56: 825-832 [PMID: 22173153 DOI: 10.1016/ j.jhep.2011.11.010]
155. Campillo B, Dupeyron C, Richardet JP. Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 2001; 127: 443-450 [PMID: 11811877 DOI: 10.1017/S095026880100628